Cancer immunotherapy: an embarrassment of riches? (Q35080226)

6 August 2017

1 reference

title

Cancer immunotherapy: an embarrassment of riches? (English)

1 reference

6 August 2017

1 reference

4

Angus Dalgleish

1 reference

6 August 2017

Mike Whelan

1

1 reference

6 August 2017

Joseph Whelan

series ordinal

2

1 reference

6 August 2017

Nick Russell

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

8

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

253-258

1 reference

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Immunological aspects of malignant disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

On cross-priming of MHC class I-specific CTL: rule or exception?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Investigation of HLA class I downregulation in breast cancer by RT-PCR

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Prognostic significance of cytokine modulation in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Decoding the patterns of self and nonself by the innate immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

The danger model: a renewed sense of self

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

BCG immunotherapy of bladder cancer: 20 years on.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Exploiting dendritic cells to improve vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

The potential of DNA vaccination against tumor-associated antigens for antitumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Trastuzumab/chemotherapy combinations in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Selectively replicating adenoviruses for oncolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902633-3

7 January 2021

10.1016/S1359-6446(03)02633-3

Identifiers

DOI

1 reference

6 August 2017

1 reference